

MEDITSIINIS KASUTATAVATE
HINGAMISGAASIAHELATE BIOSOBIVUSE HINDAMINE.
OSA 2: MIKROOSAKESTE EMISSIONI
KONTROLLKATSED

Biocompatibility evaluation of breathing gas pathways
in healthcare applications - Part 2: Tests for emissions
of particulate matter (ISO 18562-2:2024)

EESTI STANDARDI EESSÕNA

NATIONAL FOREWORD

<p>See Eesti standard EVS-EN ISO 18562-2:2024 sisaldab Euroopa standardi EN ISO 18562-2:2024 ingliskeelset teksti.</p> <p>Standard on jõustunud sellekohase teate avaldamisega EVS Teatajas.</p> <p>Euroopa standardimisorganisatsioonid on teinud Euroopa standardi rahvuslikele liikmetele kättesaadavaks 23.10.2024.</p> <p>Standard on kättesaadav Eesti Standardimis- ja Akrediteerimiskeskusest.</p>	<p>This Estonian standard EVS-EN ISO 18562-2:2024 consists of the English text of the European standard EN ISO 18562-2:2024.</p> <p>This standard has been endorsed with a notification published in the official bulletin of the Estonian Centre for Standardisation and Accreditation.</p> <p>Date of Availability of the European standard is 23.10.2024.</p> <p>The standard is available from the Estonian Centre for Standardisation and Accreditation.</p>
--	---

Tagasisidet standardi sisu kohta on võimalik edastada, kasutades EVS-i veebilehel asuvat tagasiside vormi või saates e-kirja meiliaadressile standardiosakond@evs.ee.

ICS 11.040.10

Standardite reprodutseerimise ja levitamise õigus kuulub Eesti Standardimis- ja Akrediteerimiskeskusele. Andmete paljundamine, taastekitamine, kopeerimine, salvestamine elektroonsesse süsteemi või edastamine ükskõik millises vormis või millisel teel ilma Eesti Standardimis- ja Akrediteerimiskeskuse kirjaliku loata on keelatud.

Kui Teil on küsimusi standardite autorikaitse kohta, võtke palun ühendust Eesti Standardimis- ja Akrediteerimiskeskusega: Koduleht www.evs.ee; telefon 605 5050; e-post info@evs.ee

The right to reproduce and distribute standards belongs to the Estonian Centre for Standardisation and Accreditation. No part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, without a written permission from the Estonian Centre for Standardisation and Accreditation.

If you have any questions about copyright, please contact Estonian Centre for Standardisation and Accreditation: Homepage www.evs.ee; phone +372 605 5050; e-mail info@evs.ee

EUROPEAN STANDARD

EN ISO 18562-2

NORME EUROPÉENNE

EUROPÄISCHE NORM

October 2024

ICS 11.040.10

Supersedes EN ISO 18562-2:2020

English Version

Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 2: Tests for emissions of particulate matter (ISO 18562-2:2024)

Évaluation de la biocompatibilité des chemins de gaz
respiratoire utilisés dans le domaine de la santé -
Partie 2: Essais concernant les émissions de matières
particulaires (ISO 18562-2:2024)

Beurteilung der Biokompatibilität der Atemgaswege
bei medizinischen Anwendungen - Teil 2: Prüfungen
für Emissionen von Partikeln (ISO 18562-2:2024)

This European Standard was approved by CEN on 15 March 2024.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

European foreword

This document (EN ISO 18562-2:2024) has been prepared by Technical Committee ISO/TC 121 "Anaesthetic and respiratory equipment" in collaboration with Technical Committee CEN/TC 215 "Respiratory and anaesthetic equipment" the secretariat of which is held by BSI.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by April 2025, and conflicting national standards shall be withdrawn at the latest by April 2025.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 18562-2:2020.

This document has been prepared under a standardization request addressed to CEN by the European Commission. The Standing Committee of the EFTA States subsequently approves these requests for its Member States.

For the relationship with EU Legislation, see informative Annex ZA, which is an integral part of this document.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

Endorsement notice

The text of ISO 18562-2:2024 has been approved by CEN as EN ISO 18562-2:2024 without any modification.

Contents

	Page
Foreword.....	iv
Introduction.....	v
1 Scope	1
2 Normative references	2
3 Terms and definitions	2
4 General principles	2
5 <i>Particulate matter</i> emissions	2
5.1 General.....	2
5.2 Testing methods overview.....	3
5.3 Single filter test setup.....	4
5.4 Double filter test setup.....	5
5.5 Test method.....	6
5.6 Measuring <i>particulate matter</i> emissions according to particle size.....	7
5.7 Measuring <i>particulate matter</i> emissions by particle counter.....	7
5.8 <i>Medical devices</i> with time-varying emissions.....	7
6 Reporting	8
Annex A (informative) Rationale and guidance	9
Annex B (informative) Reference to the IMDRF <i>essential principles</i> and labelling guidances	13
Annex C (informative) Reference to the <i>essential principles</i>	14
Annex D (informative) Terminology — Alphabetized index of defined terms	15
Bibliography	16

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 121, *Anaesthetic and respiratory equipment*, Subcommittee SC 3, *Lung ventilators and related equipment*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 215, *Respiratory and anaesthetic equipment*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 18562-2:2017), which has been technically revised.

The main changes are as follows:

- added informative mapping annexes to relevant regulatory requirements;
- clarified terms and definitions used in the document.

A list of all parts in the ISO 18562 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

This document is intended to protect *patients* connected to *medical devices* from excessive amounts of *particulate matter* that arises from within *gas pathways of medical devices*.

This document is intended to cover the biological evaluation of *gas pathways of medical devices* within a *risk management process*, as part of the overall *medical device* evaluation and development. This approach combines the review and evaluation of existing data from all sources with, where necessary, the selection and application of additional tests.

In general, the ISO 10993 series^[2] is intended to cover the biological evaluation of *medical devices*. However, the ISO 10993 series does not appropriately address the biological evaluation of the *gas pathways of medical devices*. For example, the ISO 10993 tests do not evaluate inspired *particulate matter*.

It is not within the scope of this document to address contamination arising from the source of the breathing gases entering such *medical devices*, but rather to address only the potential contamination generated from within the *medical device* itself. This contamination might be from the original manufacturing *process* or be generated by the *medical device* itself during use.

This document is concerned with *particulate matter* that could be conveyed to the *patient* by the breathing gases. The smaller the particle, the deeper into the lungs it can penetrate and the longer it takes the body to eliminate it. Originally, the main health concerns with regard to *particulate matter* were focused on respiratory health, but now there is emerging evidence of effects on the cardiovascular system as well.

The tests for the presence of *particulate matter* generated by respiratory *medical devices* are based on standard laboratory practice and require no advanced techniques or equipment.

The acceptable levels of contamination are based on worldwide published health data for *particulates*. It is accepted that there is no point in setting a level that is lower than that found in air that people might breathe every day of their lives.

This document has been prepared in consideration of:

- the *Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices*, IMDRF/GRRP WG/N47:2018^[5] as indicated in [Annex B](#);
- the *Labelling Principles for Medical Devices and IVD Medical Devices*, IMDRF/GRRP WG/N52:2019^[6] as indicated in [Annex B](#);
- the *essential principles of safety and performance on the information supplied by the manufacturer of a medical device* according to ISO 16142-1:2016^[3] as indicated in [Annex C](#); and
- the general safety and performance requirements of a *medical device* according to regulation (EU) 2017/745^[7].

In this document, the following verbal forms are used:

- “shall” indicates a requirement;
- “should” indicates a recommendation;
- “may” indicates a permission;
- “can” indicates a possibility or capability.

Biocompatibility evaluation of breathing gas pathways in healthcare applications —

Part 2: Tests for emissions of particulate matter

1 Scope

NOTE There is guidance or rationale for this Clause contained in [Clause A.2](#).

This document specifies tests for the emissions of *particulate matter* from the *gas pathways* of a *medical device*, its parts or *accessories*, which are intended to provide respiratory care or supply substances via the respiratory tract to a *patient* in all environments. The tests of this document are intended to quantify particles from 0,25 μm *diameter* to 10 μm *diameter* that are emitted by the *medical device*, its parts or *accessories* into the respirable gas stream. This document establishes acceptance criteria for these tests.

This document does not address nanoparticles. Insufficient data exist to establish exposure limits for particles less than 0,25 μm *diameter*.

This document does not address particles larger than 10 μm *diameter*. These particles are deposited in the nasal cavity. Additional information can be needed for *medical devices* or *accessories* that bypass the nose. This is outside the scope of this document but can be required by some *authorities having jurisdiction*.

This document therefore adopts the same approach as the US Environmental Protection Agency (EPA) in setting limits based solely on particle size and not their chemistry.

This document addresses potential contamination of the gas stream arising from the *gas pathways*, which is then conducted to the *patient*.

This document applies over the *expected lifetime* of the *medical device* in *normal use* and takes into account the effects of any intended *processing*.

This document does not address biological evaluation of the particles that are deliberately released by a nebulizer (i.e. the therapeutic agent).

This document does not address biological evaluation of the surfaces of *gas pathways* that have direct contact with the *patient*. The requirements for direct contact surfaces are found in the ISO 10993 series.

Medical devices, parts or *accessories*, containing *gas pathways* that are addressed by this document, include, but are not limited to, ventilators, anaesthesia workstations (including gas mixers), breathing systems, oxygen conserving devices, oxygen concentrators, nebulizers, low-pressure hose assemblies, humidifiers, heat and moisture exchangers, respiratory gas monitors, respiration monitors, masks, medical respiratory personal protective equipment, mouth pieces, resuscitators, breathing tubes, breathing systems filters, Y-pieces, and any breathing *accessories* intended to be used with such devices. The enclosed chamber of an incubator, including the mattress, and the inner surface of an oxygen hood are considered to be *gas pathways* and are also addressed by this document.

This document does not address contamination already present in the gas supplied from the gas sources while *medical devices* are in *normal use*.

EXAMPLE Contamination arriving at the *medical device* from gas sources such as *medical gas pipeline systems* (including the non-return valves in the pipeline outlets), outlets of pressure regulators connected or integral to a medical gas cylinder or room air taken into the *medical device* is not addressed by ISO 18562 (all parts).

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 18562-1:2024, *Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 1: Evaluation and testing within a risk management process*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 18562-1 and the following apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

NOTE For convenience, an alphabetized index of terms and their sources used in this document is found in [Annex D](#).

3.1

diameter

aerodynamic diameter

diameter of a sphere of density 1 g/cm³ with the same terminal velocity due to gravitational force in calm air as the particle of interest, regardless of its geometric size, shape and true density, under the prevailing conditions of temperature, pressure and relative humidity

[SOURCE: ISO 7708:1995, 2.2, modified — added “of interest, regardless of its geometric size, shape and true density”]

4 General principles

All *gas pathways of medical devices or accessories* shall be evaluated using the strategy detailed in ISO 18562-1.

5 Particulate matter emissions

NOTE There is guidance or rationale for this Clause contained in [Clause A.2](#).

5.1 General

a) During its *expected lifetime*, a *medical device*, part or *accessory* shall not add to the gas that could be inspired by the *patient* levels of *particulate matter*:

- 1) less than or equal to 2,5 µm *diameter*, in excess of 12 µg/m³;
- 2) less than or equal to 10 µm *diameter*, in excess of 150 µg/m³.

NOTE 1 The allowable limits are taken from the US EPA 40 § CFR Part 50^[8].

NOTE 2 These limit values are for continuous exposure to that concentration of *particulate matter*.

b) All *gas pathways of medical devices or accessories* shall be evaluated for *particulate matter* emissions. The evaluation shall use the *risk management process* to assess if testing is required.

NOTE 3 The evaluation of some components, which are identical in *formulation, processing* and preparation for use to an existing component of a *medical device* that has been previously tested, might conclude that no further testing is required. Refer to ISO 18562-1:2024, Figure 2.